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Abstract
Reduced catechol-O-methyltransferase (COMT) activity resulting from genetic variation or 
pharmacological depletion results in enhanced pain perception in humans and nociceptive 
behaviors in animals. Using phasic mechanical and thermal reflex tests (e.g. von Frey, 
Hargreaves), recent studies show that acute COMT-dependent pain in rats is mediated by β-
adrenergic receptors (βARs). In order to more closely mimic the characteristics of human chronic 
pain conditions associated with prolonged reductions in COMT, the present study sought to 
determine volitional pain-related and anxiety-like behavioral responses following sustained as 
well as acute COMT inhibition using an operant 10–45°C thermal place preference task and a 
light/dark preference test. In addition, we sought to evaluate the effects of sustained COMT 
inhibition on generalized body pain by measuring tactile sensory thresholds of the abdominal 
region. Results demonstrated that acute and sustained administration of the COMT inhibitor 
OR486 increased pain behavior in response to thermal heat. Further, sustained administration of 
OR486 increased anxiety behavior in response to bright light, as well as abdominal 
mechanosensation. Finally, all pain-related behaviors were blocked by the non-selective βAR 
antagonist propranolol. Collectively, these findings provide the first evidence that stimulation of 
ARs following acute or chronic COMT inhibition drives cognitive-affective behaviors associated 
with heightened pain that affects multiple body sites.
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Introduction
Catechol-O-methyltransferase (COMT) is an enzyme that inactivates catecholamines and 
plays a key role in a subset of common chronic pain conditions. Variants of the COMT gene 
that result in reduced activity of the corresponding enzyme are associated with experimental 
pain as well as risk of temporomandibular disorder, irritable bowel syndrome, fibromyalgia 
and low back pain (Diatchenko et al., 2005, Karling et al., 2011, Jacobsen et al., 2012, 
Martinez-Jauand et al., 2013). These functional genetic variants are also associated with 
anxiety, depression, and other psychological traits that influence the perception of pain 
(Fernandez-de-Las-Penas et al., 2012). In line with the results of human association studies, 
COMT-deficient animals exhibit increased pain and anxiety. Mice with system-wide 
deletion of COMT exhibit exaggerated behavioral responses evoked by thermal heat stimuli 
as well as by stressful acoustic stimuli (Papaleo et al., 2008, Walsh et al., 2010). Similarly, 
rats receiving an acute dose of the COMT inhibitor OR486 exhibit exaggerated responses 
evoked by thermal heat and mechanical stimuli alongside increased circulating levels of pro-
inflammatory cytokines and nitric oxide (NO), which are molecules known to sensitize 
nociceptors (Brenman and Bredt, 1997, Millan, 1999, Kress, 2004, Nackley et al., 2007, 
Kambur et al., 2010, Hartung et al., 2014). Acute COMT-dependent evoked pain as well as 
increased levels of cytokines and NO are mediated by stimulation of β-adrenergic receptors 
(βARs) (Nackley et al., 2007, Hartung et al., 2014). These findings implicate βARs in the 
pathophysiology of pain conditions associated with reduced COMT activity. Before these 
findings can be extrapolated to individuals suffering from chronic pain, however, additional 
work in a more clinically-relevant animal model is required.
Many existing animal models of chronic pain initiate pain through application of 
inflammatory agents, chemical irritants, or tissue injury and then measure evoked responses 
to standard experimental stimuli applied to the hindpaw. The initiation of pain in these 
models is relevant to conditions such as arthritis, visceral pain, and neuropathic pain, but not 
to conditions such as temporomandibular disorder and fibromyalgia. In order to more 
closely mimic the etiology of human chronic pain conditions associated with prolonged 
reductions in COMT activity, sustained systemic inhibition of COMT is required. Also, 
while chronic pain conditions often result in increased evoked responses to standard 
experimental stimuli, assessments of these behaviors do not capture the ongoing and perhaps 
more clinically-relevant nature of the pain (Wall et al., 2006, Vierck et al., 2008b). Paw 
withdrawal reflexes to phasic sensations are subserved through spinal and spinal-bulbo-
spinal loops, while perception of pain requires a cerebral cortex (Coghill et al., 1999, Vierck 
et al., 2002). Operant algesia assays require decision making behavior in order to terminate a 
perceived nociceptive stimulus and have been successfully translated from primates to 
rodents for hindpaw and visceral testing (e.g. operant escape, thermal place preference and 
conditioned place preference) (Mauderli et al., 2000, Neubert et al., 2005, Deyama et al., 
2009). A tremendous advantage of operant algesia testing is that the results better parallel 
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those obtained in humans, providing a valid indicator of clinical nociceptive sensitivity 
(Yezierski et al., 2010).
Therefore, the present study sought to determine volitional pain and anxiety-related 
behavioral responses following sustained as well as acute COMT inhibition using an operant 
10–45°C thermal place preference task and a light/dark preference test. We hypothesized 
that animals receiving the COMT inhibitor OR486 would exhibit hypersensitivity to the 
noxious 45°C surface and to bright light in a βAR-dependent manner. Further, we sought to 
evaluate the effects of sustained COMT inhibition on abdominal tactile sensory thresholds, 
hypothesizing that animals receiving OR486 would exhibit evoked hypersensitivity at a 
remote body site in a βAR-dependent manner.
As predicted, acute and sustained COMT inhibition produced consciously-motivated 
reductions in occupancy for the chamber with a floor heated to 45°C. Sustained COMT 
inhibition also produced enhanced aversion to bright light and abdominal tactile sensitivity. 
All pain and anxiety-related behaviors were blocked by the non-selective βAR antagonist 
propranolol. Together, these results demonstrate that sustained administration of the COMT 
inhibitor OR486 leads to changes in sensory and affective nociceptive responses and induces 
widespread cutaneous hypersensitivity.
Experimental Procedures
Animals and General Protocol
A total of 34 adult male Sprague Dawley rats weighing (325–425g), (Harlan Industries, 
Indianapolis IN) were housed two per shoebox cage with a reverse 12 h light/dark cycle and 
ad libitum access to food and water. Thermal and light/dark preference was evaluated in 16 
animals receiving intraperitoneal (i.p.) injections of either propranolol (3 mg/kg) or saline 30 
minutes prior to OR486 (30 mg/kg) or saline. Thermal and light/dark preference as well as 
abdominal sensitivity was evaluated in a separate set of 18 animals implanted with osmotic 
minipumps that delivered either propranolol (9 mg/kg/day) or saline alongside OR486 (15 
mg/kg/day) or saline. All procedures were approved by the University of Kentucky 
Institutional Use and Animal Care Committee and conformed to the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals.
Drugs
The COMT inhibitor OR486 was selected based on its 1) ability to cross the blood-brain 
barrier (Nissinen et al., 1988, Kambur et al., 2010), 2) good absorption and long duration of 
action (Nissinen et al., 1988), and 3) previously reported pro-nociceptive effects in rodent 
models (Diatchenko et al., 2005, Nackley et al., 2007, Kambur et al., 2010, Hartung et al., 
2014). OR486 (R&D Systems, Minneapolis, MN) was dissolved in a vehicle consisting of a 
5:2:3 ratio of dimethylsulfoxide (DMSO), ethanol and 0.9% saline. As acute i.p. or sustained 
14 day systemic delivery of this vehicle to rats has no effect on evoked mechanical/thermal 
sensitivity or non-evoked measures such as locomotor activity (Nackley et al., 2007, Ciszek 
and Nackley, 2012, Hartung et al., 2014), control groups received 0.9% saline. The general 
β-adrenergic antagonist propranolol (Sigma, St. Louis MO) was dissolved in 0.9% saline.
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Rats were anesthetized by isoflurane inhalation and surgical site prepared for aseptic 
implantation of two osmotic minipumps with a 0.5μl/hr infusion rate with a reservoir 
volume of 200μl (model 2002, Durect Corp, Cupertino, CA) slightly posterior and between 
the scapulae. Three groups of six animals received the following two-pump combinations; 
saline/saline, saline/OR486, and propranolol/OR486. The incisions (approximately 1cm) 
were closed with sutures and removed after 7 days.
Behavioral Testing
Rats were thoroughly adapted to handling and to the experimental test chambers before 
thermal and mechanical stimuli were introduced into the training regimen. Testing was 
performed in a dimly lit room with continuous white noise background following 30–60 
minutes of acclimation to the testing room. Animals were trained to asymptotic performance 
on thermal place preference during the first week prior to acute or chronic OR486 
administration. For the acute study, rats received an i.p. injection of propranolol or vehicle 
30 min prior to the COMT inhibitor OR486 or vehicle (i.p). Previous work has demonstrated 
that OR486 induces up to 2.25 hours of hypersensitivity beginning 30 minutes after injection 
(Nackley et al., 2007). This rapid onset and prolonged duration of hypersensitivity allowed 
for the consecutive assessment of light dark and thermal place preference 45 and 60 min 
after OR486 or vehicle injection, respectively in the same cohort. Similarly, in the chronic 
study, light/dark preference immediately preceded thermal place preference testing and was 
observed once weekly for two weeks. Experimenters were blind to all experimental 
conditions.
Thermal Place Preference
Thermal place preference testing is an operant assay that requires learned apportioning of 
hot or cold stimulation to determine relative thermal sensitivity. Rats resolve this conflict by 
alternating occupancy between the two compartments, with time on the cold plate positively 
related to the increasingly aversive intensity of the heat stimulus. The test apparatus 
consisted of a 27x27cm clear Plexiglas box divided by a partition into two equal halves. A 
2.5″ x 2.5″ opening in the center of the partition permitted free movement between sides. 
The floor of each side was a separate aluminum thermal plate which allowed independent 
temperature control. The position of the rats was monitored in real time for 10 minutes by 
continuous observation using a custom-designed computer program which captured the 
number of crossings and amount of time spent on each side (Vierck et al., 2002). It was 
determined during initial training that if the floor on one side was 10°C and the other side 
was at 45°C rats spent about equal amounts of time on either side. Occupancy of the heated 
plate is known to be noxious since low dose morphine increases occupancy for the 45°C 
surface (Vierck et al., 2002). Dependent measures were: 1) cumulative heat – cold 
occupancy, 2) total amount of rearing behavior and 3) the initial hot-to-cold transition 
latency. Surface temperature of the floor plates was monitored with an electronic 
thermometer (model 4000, YSI Inc., Yellow Springs, OH). Cumulative thermal preference 
was plotted, response by response, as difference scores (45°C - 10°C plate durations for the 
first occupancy, then 45°C - 10°C plate durations for the second occupancy etc.). The 
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cumulative response format provides advantages by emphasizing the 1) effective illustration 
of continuous decision based behavior between two sensory stimuli and 2) that the assay 
provides and displays responses to repetitive thermal stimuli which indicates pain tolerance 
rather than a sensory threshold. These temporally summative response formats are similar to 
the pain-score formats of clinical studies, which also applied continuously repetitive stimuli, 
necessary to evaluate the temporal modification of tonic stimuli (Vierck et al., 2001). This 
conventional method of display has been consistently reported for both operant escape and 
thermal place preference tests (Vierck et al., 2008a, Yezierski et al., 2010, Vierck et al., 
2013, Yezierski et al., 2013). For both acute and chronic studies, thermal place preference 
testing was preceded immediately by a light/dark preference test.
Light/Dark Preference
The light/dark box test is a widely used method for detection of anxiety-like behaviors based 
upon the dark preference of animals when paired with a brightly-lit alternative. The test 
apparatus consisted of a 27x27cm Plexiglas box divided by a partition into two equal halves, 
one half was opaque (dark) while the other half was transparent. A 2.5″ x 2.5″ opening in 
the center of the opaque partition permitted free movement between the light and dark 
chambers. A 12 inch 15 watt fluorescent bulb lamp (725 lumens) was located along the 
exterior top horizontal edge of the transparent side for illumination. One half of the test 
chamber lid was transparent while the other half was black, allowing for near complete 
darkness. Dependent measures were: 1) cumulative dark – light occupancy, 2) total amount 
of light-side activity (rearing) and 4) the initial dark-to-light transition latency over the 10 
minute place preference test (Parent et al., 2012).. Cumulative light/dark preference was 
plotted, response by response, as difference scores (dark - light chamber durations for the 
first occupancy, then dark - light chamber durations for the second occupancy etc.). As with 
thermal place preference, light/dark preference data are presented as a cumulative preference 
which displays a summative result consequent to multiple trips into and out of the bright 
light. For the chronic study, light/dark preference testing was always preceded by abdominal 
mechanical allodynia testing after a 1 hour room acclimation.
Abdominal von Frey
Tactile allodynia was determined using low to high bending force calibrated nylon 
filaments, measuring the withdrawal frequency (%) of 10 repeated abdominal applications to 
3.61, 4.08 and 4.31g respectively. Applications were approximately 1 s in duration with an 
interstimulus interval of 1–30 s. Tactile allodynia was defined as an increase in the 
percentage frequency ([No. of abdominal withdrawals/10]X100) of evoked abdominal 
withdrawal. Positive abdominal withdrawal responses consisted of raising or flexion of the 
abdomen from a rested position with floor contact. Abdominal skin was shaved with 
clippers once each week one day prior to testing. Rats were handled and habituated to the 
test environment (7cm x 4 cm x 4cm clear Plexiglas enclosures on a raised metal mesh 
platform) during 3 baseline sessions one week prior to osmotic pump implantation. 
Behavioral responses to mechanical stimuli were assessed at baseline and 14 days after 
osmotic pump implantation. The intraperitoneal injection route of delivery precluded the 
assessment of OR486 on abdominal sensitivity.
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T-test, One and Two-way ANOVA were used for comparison of 1) thermal place preference 
hot-to-cold transitions, plate occupancies, transition latencies and exploratory activity 
(rearing), 2) light/dark box light-to-dark transitions, light occupancy, transition latencies and 
light side activity (rearing) and 3) frequency of withdrawal to abdominal application of von 
Frey filaments with a minimum significance level of p<0.05 to reject the null hypothesis 
using SigmaPlot software (SPSS, Chicago, IL). Tukey’s test was used for pairwise post-hoc 
comparisons within the ANOVA analysis.
Results
Effects of acute and sustained OR486 on thermal place preference
To determine if acute and chronic COMT inhibition preferentially affect heat or cold 
sensitivity, we assessed 10°C vs. 45°C thermal place preference responses in the acute 
cohort one hour after OR486 injection or 7 and 14 days after continuous OR486 infusion in 
the chronic cohort. Stable baseline performance was noted as none of the occupancies for 
heat in the last three baseline sessions (48.0+3.4%, 55.6+3.7%, and 44.4+2.1%, 
respectively) were significantly different from one another by one-way ANOVA (P > 0.05; 
data not shown). As shown in Figure 1A, animals receiving acute OR486 exhibited a 
significant increase in preference for the 10°C plate compared to those receiving saline or 
OR486 with propranolol pre-treatment over the 10 minute test duration (P < 0.001, df = 2, F 
= 33.12, by Two-way ANOVA). Furthermore, animals receiving propranolol prior to OR486 
did not differ from saline controls (P=0.065, Two-way ANOVA). As shown in Figure 1B, 
animals receiving sustained administration of OR486 exhibited increased preference for the 
10°C plate after 7 days compared to those receiving saline (P < 0.001) or OR486 with 
propranolol pre-treatment (P < 0.005, df = 2, F = 8.23, by Two-way ANOVA). There were 
no significant differences between treatment groups 14 days after continuous infusion (data 
not shown). We attribute the differences in the 45°C plate occupancies between the acute 
and chronic cohorts possibly resulting from the difference in the experimental procedures; 
the acute cohort underwent repeated i.p. injection while the chronic cohort underwent 
surgical implantation of osmotic minipumps. Thermal preference is shown as difference 
scores of the cumulative responses. (heat – cold duration for the first occupancy within each 
side of the test chamber, plus heat – cold duration for the second occupancy, etc). These 
observations demonstrate that both acute and chronic COMT inhibition decrease thermal 
place preference for noxious 45°C heat via βAR signaling at day 7.
Effects of acute and sustained OR486 on light/dark preference
To determine the effects of acute and chronic COMT inhibition on anxiety-like behavior, we 
assessed behavior in a light/dark preference test 45 min after OR486 injection in the acute 
cohort or 7 and 14 days after continuous OR486 infusion in the chronic cohort. As shown in 
Figure 2A, animals receiving a single dose of OR486 did not exhibit differences in light/
dark preference (P = 0.26, by Two-way ANOVA). This insignificant trend continued even 
after 7 days of continuous OR486 infusion (data not shown). In contrast, animals receiving 
sustained administration of OR486 for 14 days had increased preference for dark compared 
to those receiving saline or OR486 with propranolol (P < 0.001, df = 2, F = 12.2, by Two-
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way ANOVA; Figure 2B). We attribute the increased dark side occupancy in the acute 
cohort compared to the chronic cohort, as anxiety-like behavior possibly resulting from two 
sequential i.p. injections as a single i.p. saline injection is capable of producing pain-like and 
anxiety-like behavior (Lapin, 1995). Light/dark preference is shown response by response as 
difference scores (dark - light duration for the first occupancy within each side of the test 
chamber, plus dark - light duration for the second occupancy, etc.). These data indicate that 
chronic, but not acute COMT inhibition, produces anxiety-like behavior that is mediated by 
βARs.
Effects of acute and sustained OR486 on exploratory activity
OR486 administration had minimal effects on exploratory behavior during thermal and light/
dark preference testing. In the thermal preference test, acute but not chronic OR486 
significantly reduced the first hot to cold transition latency compared to acute saline, 
consistent with sensitivity to 45°C heat (P <0.01, T-test) (Table 1). Increased rearing 
behavior and decreased transition latencies were observed in both chronic treatment groups 
compared to acute treatment groups (P < 0.001, T-test). Likewise in the light/dark 
preference test, increased rearing behavior and decreased transition latencies were observed 
in both chronic treatment groups compared to acute treatment groups (P < 0.001, T-test) 
(Table 1). Prolonged latencies to enter the light chamber in the acute cohort compared to the 
chronic cohort further supports the conclusion that repetitive i.p. injections produced 
anxiety-like behavior. Similar changes in behavior in chronic study animals, saline and 
OR486, were seen compared to acute study animals. Propranolol either co- or pre-
administered with OR486 had no effect on these exploratory behaviors compared to OR486/
saline co-administration indicating no adverse effects. We attribute the overall differences in 
exploratory activity between the acute and chronic cohorts possibly due to the anxiety-
provoking effects of repetitive i.p. injections in the acute but not the chronic cohort (Lapin, 
1995).
Effects of sustained OR486 on abdominal sensitivity
To determine the effects of chronic COMT inhibition on mechanosensation of the 
abdominal skin, we assessed the abdominal withdrawal frequency to von Frey filament 
application after 14 days of continuous OR486 infusion. Figure 3 demonstrates that animals 
receiving OR486 exhibit a significant increase in abdominal withdrawal frequency 
compared to those receiving saline (P < 0.006, df = 2, F = 6.47, by Two-way ANOVA). 
Animals receiving continuous propranolol and OR486 had attenuated responses to the 3.61 
and 4.08 g stimuli compared to those receiving saline and OR486 (P < 0.02, df=2, F = 6.47, 
by Two-way ANOVA). These observations demonstrate that chronic COMT inhibition 
produces abdominal mechanical hypersensitivity that is mediated by βARs.
Discussion
Here, we provide the first demonstration that stimulation of βARs following acute or chronic 
COMT inhibition drives cognitive-affective behaviors associated with heightened pain. 
Compared to animals receiving saline, those receiving an acute injection or continuous 
infusion of the COMT inhibitor OR486 exhibited pronounced sensitivity to noxious 45°C 
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heat, preferring the 10°C cold. Animals receiving continuous infusion of OR486 also 
exhibited a greater sensitivity to bright light, preferring the dark. Furthermore, we show that 
chronic COMT inhibition leads to increased mechanosensation on the abdominal skin. 
COMT-dependent increases in pain and anxiety-like behaviors were blocked by the 
nonselective β-adrenergic antagonist propranolol.
These findings are in line with those from earlier studies showing that stimulation of βARs 
following acute COMT inhibition leads to increased pain evoked by thermal heat or punctate 
mechanical stimuli on the footpad (Nackley et al., 2007, Hartung et al., 2014). Compared to 
assays of evoked withdrawal responses, the operant assays used herein require decision 
making behavior in order to terminate a perceived threatening stimulus. Thus, reduced 
occupancy on the heated plate following OR486 administration may be interpreted as 
enhanced perception of peripheral noxious heat. In support of this interpretation, subjects 
with the low (158met) versus high (158val) COMT activity allele exhibit stronger functional 
Magnetic Resonance Imaging (fMRI) signals in pain-relevant cortical and sub-cortical 
regions during presentation of noxious thermal heat (Loggia et al., 2011). Of note, the 
thermal heat intensities used in earlier Hargreaves and hot plate assays of evoked pain were 
higher (47°–50°C) than used here (Nackley et al., 2007, Kambur et al., 2010, Hartung et al., 
2014), likely stimulating different populations of nociceptors (Yeomans and Proudfit, 1996). 
Higher temperatures preferentially activate Aδ nociceptors, while temperatures ranging 43°–
45°C preferentially activate C-thermal nociceptors (Yeomans and Proudfit, 1996, Vierck et 
al., 2002). Thus, past and present studies together provide behavioral evidence for COMT-
dependent sensitization of both Aδ and C-thermal nociceptors. Further characterization of 
operant responses and nociceptor physiology during periods of low COMT activity may 
prove useful to the study of chronic pain, as patients with temporomandibular disorders and 
fibromyalgia have abnormal nociceptor function in response to a similar range of moderate 
to high intensity temperatures (Maixner et al., 1995, Maixner et al., 1998, Park et al., 2010, 
Vierck et al., 2014).
In addition to enhanced pain amplification, patients with chronic pain often experience high 
levels of stress and anxiety, which are traits also mediated by COMT (Vassend et al., 1995, 
Thieme et al., 2004, Fernandez-de-Las-Penas et al., 2012). Using a light/dark assay, we 
found that sustained, but not acute, administration of OR486 resulted in anxiety-like 
behavior defined by reduced light side activity. These data are in agreement with those 
published by Desbonnet and colleagues, who show that life-long inhibition of COMT in 
COMT null mice produces anxiety-like behavior, while acute administration of the COMT 
inhibitor tolcapone to wildtype mice fails to alter light/dark performance (Desbonnet et al., 
2012). Furthermore, COMT null mice display increased acoustic startle amplitude along 
with decreased novel object exploration and decreased open arm entries in an elevated plus 
maze (Papaleo et al., 2008). Consistent with genetic studies in mice, fibromyalgia patients 
with the low (158met) COMT activity allele experience increased levels of depression and 
anxiety (Fernandez-de-Las-Penas et al., 2012). The influence of COMT on psychological 
traits such as anxiety is generally thought to be mediated by dopaminergic signaling in the 
pre-frontal cortex. However, the ability of propranolol to normalize light-dark preference in 
the chronic COMT inhibition model suggests that this view needs to be expanded to include 
adrenergic systems (Smolka et al., 2005).
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The present findings describe a novel relationship between COMT inhibition and volitional 
pain-related behaviors. As these measures are sensitive to changes in exploratory behavior 
(Mauderli et al., 2000), we also evaluated the effects of acute and sustained OR486 
administration on rearing during the thermal preference assay and transition latency during 
the light/dark preference assay. No deleterious effects of OR486 were observed on 
exploratory activity during either of these assays. In support of this association, 
pharmacologic inhibition or genetic knockdown of COMT in mice does not affect 
ambulation or exploratory activity (Papaleo et al., 2008, Desbonnet et al., 2012). We, 
therefore, conclude that COMT-dependent decreases in heat and light preference are indeed 
due to increased nociception.
Another hallmark of chronic musculoskeletal pain conditions is that patients often 
experience generalized sensory abnormalities at remote bodily sites (Gracely et al., 1992, 
Gracely et al., 2003, Giesecke et al., 2004, Vierck, 2006). In order to evaluate the 
generalized nature of chronic COMT inhibition, we evaluated withdrawal responses to 
innocuous tactile stimuli applied to the abdominal region. Our findings extend earlier work 
by demonstrating that COMT inhibition produces increased mechanosensation on the hairy 
skin of the abdomen as well as the glabrous skin of the hindpaw (Nackley et al., 2007, 
Kambur et al., 2010, Hartung et al., 2014). This phenomenon is likely driven by 
neurophysiologic changes in the central nervous system that increase central responses to 
peripheral stimuli (Gracely et al., 1992, Bohm-Starke et al., 1998, 1999, Giesecke et al., 
2004). Indeed, work by Desmeules and colleagues demonstrate that fibromyalgia patients 
exhibit a linear relationship between COMT val158met genotype and magnitude of spinal 
nociceptive flexion reflex, a physiologic correlate of central sensitization, such that patients 
with two copies of the val allele have the highest reflex thresholds and those with two copies 
of the met allele have the lowest reflex thresholds (Desmeules et al., 2012). Additionally, 
patients using COMT inhibitors for the treatment of Parkinson’s disease report heightened 
visceral and generalized pain (Gordin et al., 2004).
The ability of propranolol to block both volitional pain and anxiety-related behaviors as well 
as evoked pain responses at multiple sites following prolonged reductions in COMT is 
consistent with clinical observations that βAR antagonists provide pain relief for patients 
with FM and TMD (Wood et al., 2005, Light et al., 2009, Tchivileva et al., 2010). 
Furthermore, results from a randomized controlled trial demonstrate that the βAR antagonist 
propranolol provides significant pain relief for TMD patients who carry the low activity, but 
not high activity, COMT genotype (Tchivileva et al., 2010). However, more work is 
required to evaluate the role of specific βAR subtypes in mediating the development and 
maintenance of volitional COMT-dependent pain behaviors.
Propranolol is a nonselective βAR antagonist able to block β1-, β2-, and β3AR subtypes at 
doses similar to the one used herein (O’Donnell et al., 1994, Tsujii and Bray, 1998). 
Previously, our group has shown that evoked COMT-dependent pain behaviors following 
OR486 administration are mediated by β2- and β3AR subtypes (Hartung et al., 2014). β2- 
and β3ARs are G protein-coupled receptors expressed in peripheral, spinal, and central 
regions where they could potentially mediate pain sensitivity. In the periphery, β2ARs are 
located on mononuclear leukocytes (Landmann, 1992), adipocytes (Kobilka et al., 1987), 
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vascular, uterine, and airway smooth muscle cells (Dixon et al., 1986). In the central nervous 
system, β2ARs are located on thalamic, cerebellar (Rainbow et al., 1984, Nicholas et al., 
1996), and spinal dorsal horn neurons (Nicholson et al., 2005) as well as glial cells (Stone 
and Ariano, 1989, Salm and McCarthy, 1992). The contribution of β2ARs to enhanced pain 
sensitivity is in line with results from previous studies demonstrating that epinephrine 
activates β2ARs located on primary afferent nociceptors and produces a hyperalgesic state in 
rats (Khasar et al., 1999a, Khasar et al., 1999b, Aley et al., 2001, Khasar et al., 2003). 
Additionally, common variants of the human β2AR gene, coding for differences in receptor 
expression and internalization, are associated with the onset of TMD (Diatchenko et al., 
2006). β3ARs are mainly expressed in brown and white adipose tissue, where their 
activation produces robust increases in pro-inflammatory cytokines (Mohamed-Ali et al., 
2001). Recently, they have been shown to drive norepinephrine-induced ATP release in 
dorsal root ganglia (DRG) as a contributor to neuropathic pain behavior (Kanno et al., 
2010). β2- and β3ARs drive COMT-dependent pain, at least in part, by promoting the release 
of NO and the innate immunity cytokines tumor necrosis factorα, interleukine-1β, and 
interleukin-6, which in turn produce heightened pain sensitivity. While β2- and β3ARs and 
their downstream effectors may also mediate the development and maintenance of volitional 
COMT-dependent pain behaviors, additional pharmacologic studies are required to 
determine if this is the case.
Furthermore, additional pharmacologic studies are required to determine the potential effects 
of the OR486 vehicle on volitional pain behaviors. Acute i.p. or sustained 14 day systemic 
delivery of this vehicle to rats has no effect on evoked mechanical/thermal sensitivity or 
non-evoked measures such as locomotor activity (Nackley et al., 2007, Ciszek and Nackley, 
2012, Hartung et al., 2014), thus control groups herein received 0.9% saline. This represents 
a limitation of our study as it is possible that vehicle effects might change as a function of 
different experimental protocols.
Finally, it is important to note that the influence of COMT on pain and anxiety-related 
behaviors is likely modified by sex. It is well-established that males and females differ with 
respect to COMT activity levels, with males exhibiting higher levels in brain (Chen et al., 
2004) and peripheral tissues (Boudikova et al., 1990). A growing literature continues to 
demonstrate that the effects of COMT on nociception, cognition, and behavioral traits such 
as anxiety are sexually dimorphic, with the magnitude and direction of the effect being 
highly assay-dependent (Gogos et al., 1998, Harrison and Tunbridge, 2008, Papaleo et al., 
2012, Belfer et al., 2013, Sannino et al., 2014, White et al., 2014). As the present study only 
included males, future studies should also be conducted to explore interactions between sex 
and COMT/adrenergic signaling on pain and cognitive-affective behaviors.
Conclusions
Taken together, these findings provide the first evidence that stimulation of βARs following 
acute or chronic COMT inhibition drives cognitive-affective behaviors associated with 
heightened pain that affects multiple body sites. Moreover, these data support the chronic 
COMT inhibition model as a novel animal model that 1) mimics genetic and phenotypic 
characteristics of human persistent pain conditions and 2) has utility to elucidate the key 
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mechanisms underlying chronic pain conditions associated with abnormalities in COMT and 
catecholamine signaling. Finally, these data have important clinical implications, suggesting 
that βAR antagonist therapy may prove useful in suppressing pain at multiple levels 
associated with the transmission and perception of pain.
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The chronic COMT inhibition model mimics genetic and phenotypic traits of human 
pain
Chronic COMT inhibition leads to heightened cognitive-affective pain behaviors
Chronic COMT-dependent pain affects multiple body sites
Chronic COMT-dependent pain is mediated by β-adrenergic receptors
Kline et al. Page 16














Acute and chronic COMT inhibition produces thermal hyperalgesia in a 10°–45°C thermal 
place preference task of 10 minutes duration. Administration of (A) a single dose of OR486 
(30mg/kg) effective for one hour or (B) continuous delivery of OR486 (15 mg/kg/day) for 7 
days, led to increased preference for 10°C. COMT-dependent thermal hyperalgesia was 
blocked by a single dose of propranolol (3 mg/kg) prior to acute OR486 or by continuous 
delivery of propranolol (9mg/kg/day) concurrently with sustained OR486. The cumulative 
plots were constructed by summing the first time of occupancy on the cold plate with the 
first duration on the hot plate, response by response, in order to generate the group means 
shown. N= 8–16 per group. *p<.001 compared to Saline, Saline and Propranolol, OR486. 
#p<0.005 compared to Propranolol, OR486.
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Chronic, but not acute COMT inhibition, produces anxiety-like behavior. (A) Acute OR486 
(30mg/kg) administration did not significantly increase occupancy for the dark chamber. (B) 
Continuous delivery of OR486 (15mg/kg/day) for 14 days increased preference for the dark 
chamber in the 10 minute light/dark place preference test. This effect was blocked by 
continuous co-administration of propranolol (9mg/kg/day). The cumulative plots were 
constructed by summing the first time of occupancy on the light side from the first duration 
on the dark side, response by response, in order to generate the group means shown. N= 6–
16 per group. *p<.01 compared to Saline, Saline.
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Chronic COMT inhibition produces innocuous abdominal tactile hypersensitivity in the 10 
minute light/dark place preference test. Continuous delivery of OR486 for 14 days 
(15mg/kg/day) resulted in increased abdominal withdrawal frequency to 3.61, 4.08 and 
4.31g von Frey filaments. Co-administration of propranolol (9mg/kg/day) blocked OR486-
induced increases in withdrawal frequency to the 3.61 and 4.08, but not the 4.31g filaments. 
Results are expressed as mean ± SEM. N= 6 per group. *p<.01 compared to Saline, OR486. 
#p<0.01 compared to Saline, Saline.
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Table 1
Rearing and transition latency behaviors during thermal and light-dark preference testing
Thermal Preference Testing
Acute Chronic
Saline OR486 Saline OR486
Rearing 31.25 (3.8) 32.8 (3.3) 67.0 (4.5) # 49.1 (4.3)*#
Latency 16.9 (2.9) 9.6 (2.8)# 4.3 (0.9)# 5.6 (1.3)#
Light-Dark Preference Testing
Acute Chronic
Saline OR486 Saline OR486
Rearing 5.2 (1.1) 5.8 (1.1) 17.2 (2.3) # 14.2 (1.5)#
Latency 203.1 (81) 167.9 (80) 20.0 (5.1) # 18.3 (2.6)#
N=6–16 per group.
*
p<0.01 vs saline and
#
p<0.001 acute vs chronic. Results are expressed as mean ± SEM.
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